![]() ![]() The aim of the present analysis was to assess the process of attack diagnosis in N-MOmentum. Eighteen attack criteria were defined by the study steering committee and revised following the US Food and Drug Administration feedback. 6 In the absence of consensus criteria for NMOSD attack diagnoses at the time of study initiation, specific criteria were defined to enhance uniform diagnosis of attacks. N-MOmentum was a randomized, placebo-controlled, double-blind, phase 2/3 study assessing the efficacy and safety of inebilizumab, an anti-CD19, B-cell depleting antibody, in participants with NMOSD that met the primary endpoint on delaying time to attack. ![]() ![]() Attack diagnosis is imperative to monitor treatment response, yet well-defined, universally accepted criteria for accurate and objective diagnosis of NMOSD attacks are lacking. 1, 4, 5 NMOSD attacks result in destruction of astrocytes and surrounding tissue, are often severe, and recovery is frequently incomplete despite treatment. 1 – 3 Up to 90% of patients with NMOSD have pathogenic autoantibodies to the water channel protein aquaporin-4 (AQP4) found on astrocytic foot processes. Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune central nervous system disease characterized by recurrent disabling attacks of optic neuritis, transverse myelitis, and, less commonly, brain or brainstem inflammation. ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |